Clinical Trial Update: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole [Phase 3]

View source ↗

Summary

Phase 3 results from the BOLERO-2 trial show that adding everolimus to exemestane improved progression-free survival in postmenopausal women with estrogen recep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Aromasin (exemestane)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-08-31